MDBIO VENTURES
MDBIO VENTURES
Seed and Early Stage Investments
MDBio Ventures is the investment arm of the MD Biosciences with over 30 years of experience, and expertise in early-stage drug and device development. Our focus is exclusively on Seed and Series A stage companies developing the next generation of pharmaceutical, diagnostic, and medical device technologies. We are building our partnership model to invigorate other companies and bold programs that will help shape the future of healthcare and benefit humanity.
WE RELISH EARLY-STAGE IDEAS AND THEIR POTENTIAL…
Most ground-breaking therapies, devices or diagnostics had their start somewhere in the universe of early-stage development, whether in academia or a start-up. The road to market starts with de-risking such technologies, proving their concept, showing utility, or defining the toxicity profile. The journey can be costly and depends on making critical choices. This is the nature of an early-stage venture and the potential outcome of seed or early investments into unproven technologies. Consequentially, many venture capitalists are shying away from investments. In many cases, the risk is perceived because the science and potential is not understood.
It’s clear that everyone should reduce risk where possible, and we do the same. Our risk mitigation strategy is simple: we know the sciences, we can look back at nearly 30 years of experience and decide with a fair bit of confidence that the approach, technology, or solution being presented merits the next investment of resources.
We will perform our own due-diligence by studying the available data and in cases where we feel that more is needed, we may also run our own quick confirmatory study at our cost and provide you with the data.
…BUT WE DON’T RELISH GROUP-THINK
In many instances, potential investors may hedge their risk by following the pack, relying on the insight of others to drive their investment decision. Group-thinking is a vestige of risk mitigation when investors are unable to ascertain the potential of a new technology due to the lack of scientific resources or experience. We like to think for ourselves.
We like to consider true unmet needs, where the market itself may not even realize that a need exists, and where, for example, a traditional method or procedure that may have been used and taught for decades can be questioned and replaced. We like to attack the fortress of That’s-Just-How-Things-Are-Done and ask, why?
WE INVEST WITH YOU TO INCREASE VALUE.
A typical early-stage program requires up to approximately $2 Million in laboratory work. Such work is sometimes performed in-house but is more commonly handed to multiple contract research laboratories. This work is an unavoidable cash drain and this is where we step in.
We invest by taking larger cost portions of necessary, expensive studies such as cell-based assays, biomarker analyses, small and large animal studies, GLP toxicology, pathology, and where possible, into biological manufacturing. We provide scientific guidance and support to our investment partner.
MDBV-1
A $50 MILLION
IN-KIND INVESTMENT FUND
Our Fund 1 will provide up to $50 Million in-kind value for a portfolio of 30 companies. Commitment size will be between $250,000 to $2.5 Million*.
Fund 1 is focused on the following areas in seed or Series A stage:
Neurodegenerative diseases
Wound Healing
Oncology
AI- Drug Discovery, Screening and Development
Surgical tools
Diagnostics
LET'S TALK!
We are excited to hear from you.
Send us your non-confidential deck or summary email to start the conversation. E-mails can be sent to Launch(at)MdbioVentures.com
Thank you!